{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/acne-vulgaris/prescribing-information/topical-retinoids/","result":{"pageContext":{"chapter":{"id":"6d9ac0d3-8378-55b8-b6dc-17fb87472c20","slug":"topical-retinoids","fullItemName":"Topical retinoids","depth":2,"htmlHeader":"<!-- begin field 26df250d-b3d7-4be0-88b6-305cccc49432 --><h2>Topical retinoids</h2><!-- end field 26df250d-b3d7-4be0-88b6-305cccc49432 -->","summary":"","htmlStringContent":"<!-- begin item 710c9701-5e93-411a-837b-0a8889eae9f1 --><!-- end item 710c9701-5e93-411a-837b-0a8889eae9f1 -->","topic":{"id":"4f10413c-64a7-5bb3-9003-1093b58e5700","topicId":"7737f6eb-1907-461e-a10b-166056e652b7","topicName":"Acne vulgaris","slug":"acne-vulgaris","lastRevised":"Last revised in August 2020","chapters":[{"id":"c13b5a16-bcf3-5b36-8dce-af226250264d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"318cce93-72af-5473-9c96-2577e69df14c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6aac7922-c920-5394-bc2c-08ae3e93e4c5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b6ea59d7-e11c-59ba-ae3a-d12eda1c224b","slug":"changes","fullItemName":"Changes"},{"id":"501eff80-f5ab-5966-b79a-791cec9fcf7c","slug":"update","fullItemName":"Update"}]},{"id":"017f5393-8a9f-5cdb-9799-d9c32c6b50e9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"32769738-e7d1-5c7a-a6ac-7e242b6ad659","slug":"goals","fullItemName":"Goals"},{"id":"60cde7a9-d789-5629-a7d6-e14882c6caf9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f91e328f-4d37-5a01-ab6d-edf7165acdaf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01961474-a4a0-5330-bc03-aca2c93fd7ed","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"867bb680-22ea-5d29-88b0-f219f9e8dae8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8447443c-c6e1-5af4-ab33-68aa460c97b0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10279ff1-6a1f-5af9-97b1-73405139911f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13ced928-40f6-593c-8ae8-3d619c885e2e","slug":"definition","fullItemName":"Definition"},{"id":"290d67e9-4d5f-5a03-bafc-46380a14e964","slug":"causes","fullItemName":"Causes"},{"id":"2c90cfb7-ff4f-535b-b067-7b291de8de21","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5665dddd-4418-59f5-8480-8d73bc88b392","slug":"complications","fullItemName":"Complications"},{"id":"8e63da8e-8783-584a-962f-77fc8f5cda7c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cac20ff4-4d28-5a3d-ab66-5ad66ea6485d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"318b12a5-f38e-5aa0-866d-258e0bc4606b","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"00cb6f19-98f0-5279-8ca3-56e9898a856b","slug":"assessment","fullItemName":"Assessment"},{"id":"9a6b352b-2522-507b-baee-3746ed6c5fc1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"93060cf3-048d-55d8-b979-1ee7c8b333d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"8708236c-483d-548a-bcbb-ece4a63d3ef2","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"}]},{"id":"ff879f6d-4cca-54e7-b137-1bea3673664f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9958ec-2ef2-5cdd-8066-9039ba251071","slug":"benzoyl-peroxide","fullItemName":"Benzoyl peroxide"},{"id":"6d9ac0d3-8378-55b8-b6dc-17fb87472c20","slug":"topical-retinoids","fullItemName":"Topical retinoids"},{"id":"b3431b25-388f-5ae4-9ae3-fe13143c5d26","slug":"topical-antibiotics","fullItemName":"Topical antibiotics"},{"id":"9ca57669-ad06-5179-885d-5b8063e1323f","slug":"azelaic-acid","fullItemName":"Azelaic acid"},{"id":"8ae4cfcf-ffa5-5d2f-b469-369a52c50963","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"dd897071-f76b-5e49-9c2d-e98f4b853afa","slug":"combined-oral-contraceptives","fullItemName":"Combined oral contraceptives"}]},{"id":"1a455bee-cdcd-5bfe-ac3c-92ebf7dc4f1b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c326d983-7898-5757-a2dd-0324dc5bca9a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7efc9e19-3f3c-5fe4-86af-6645e982294d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5133582b-9a2b-5faf-a3be-a014b639deef","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"10179a08-abca-5ecd-982e-b1147cb710a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25e71f93-96a6-5694-a7be-371938647a37","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2adb6ee6-1991-50db-bb70-4a7b3d113064","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9f2f3c9d-3968-50fd-88cb-555214f14d6b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ff879f6d-4cca-54e7-b137-1bea3673664f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c8e04c58-5cf9-58d9-8c33-7f7826605b5f","slug":"prescribing-issues","fullItemName":"Prescribing issues","depth":3,"htmlHeader":"<!-- begin field 554ac123-1431-497f-9bc4-12a200d0147c --><h3>Topical retinoids</h3><!-- end field 554ac123-1431-497f-9bc4-12a200d0147c -->","summary":"","htmlStringContent":"<!-- begin item aa67bdb8-84ef-4cf7-917e-3d9503bc44f5 --><!-- begin field 6638f94d-37ad-426e-b136-ddcd3e588da2 --><h4>Indication and dose for mild to moderate acne vulgaris</h4><ul><li>Adapalene and tretinoin are the topical retinoids licenced for use in children over the age of 12 and adults in the UK. Topical isotretinoin is licenced for use in adults only.</li><li>Application is usually once or twice a day and varies between agents — for information on specific products see the <a href=\"https://bnf.nice.org.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"a8f3ad4f-5084-4278-8ef9-a993004ee056\">British National Formulary</a> (BNF) and the <a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"9a3461f4-69dc-4f67-bc47-a993004ee11a\">Summary of Product Characteristics</a>.</li><li>If peeling due to use of other irritant acne treatments is present, allow to subside before starting a topical retinoid — discontinue use if severe irritation occurs.</li><li>Topical retinoids should be used sparingly to cover the whole affected area and not just on visible spots — if the person has sensitive skin, initiate therapy at a lower frequency (for example three times per week) and increase to daily use as tolerated.</li><li>Concomitant use of a noncomedogenic moisturizer and sunscreen may also help tolerability.</li></ul><h4>Contraindications and cautions</h4><ul><li>Hypersensitivity to the active substance or to any of the excipients.</li><li>Avoid in pregnancy and breastfeeding — women of child-bearing age must use effective contraception.</li><li>Avoid in people with severe acne, perioral dermatitis, rosacea or a personal or family history of non-melanoma skin cancer.</li><li>Avoid accumulation in angles of the nose and contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin.</li><li>Avoid exposure to excess UV light (including sunlight and solariums) — if sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.</li></ul><h4>Adverse effects</h4><ul><li>Skin irritation including discomfort, blistering of skin, burning, crusting, dryness, peeling, erythema, oedema, pruritus, stinging, contact dermatitis and temporary changes of skin pigmentation.</li><li>Eye irritation.</li><li>Increased sensitivity to UV light — if sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.</li></ul><h4>Interactions</h4><ul><li>Systemic absorption may follow topical application of isotretinoin and prescribers should be aware of the possibility of interactions — for further information see the <a href=\"https://bnf.nice.org.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"6adc7d61-cf22-4a7d-ae97-a993004ee18a\">BNF</a>.</li><li>Other retinoids or drugs with a similar mode of action should not be used concurrently.</li><li>Avoid use of topical retinoids with abrasive cleaners, comedogenic or astringent cosmetics.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Eichenfield, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">ABPI, 2018b</a>]</p><!-- end field 6638f94d-37ad-426e-b136-ddcd3e588da2 --><!-- end item aa67bdb8-84ef-4cf7-917e-3d9503bc44f5 -->","subChapters":[]},{"id":"b5dc3a61-17ba-50fd-aa24-bb1804ab939f","slug":"combining-with-other-drugs","fullItemName":"Combining with other drugs","depth":3,"htmlHeader":"<!-- begin field 60f1dca4-8e59-48df-81da-248228220649 --><h3>How should topical retinoids be combined with other drugs?</h3><!-- end field 60f1dca4-8e59-48df-81da-248228220649 -->","summary":"","htmlStringContent":"<!-- begin item e98def1f-243e-4d3b-9d6a-a46892bf760e --><!-- begin field 517ee9c9-4ea0-4150-9623-113e494a0890 --><ul><li>Topical retinoids are often used in combination with other topical drugs. This can be done by alternating separate products or by using proprietary combination products. The choice should be made according to individual preference and cost, bearing in mind that combined proprietary drugs:<ul><li>Do not allow for individual titration of component drugs.</li><li>Are usually formulated with an alcoholic base, which may irritate sensitive skin.</li><li>May be more expensive than the individual generic component (which can be applied simultaneously with equivalent effects).</li></ul></li><li>A topical retinoid combined with a benzoyl peroxide is a useful choice, especially in the maintenance of acne.<ul><li>Apply the products once daily, 12 hours apart (for example the topical retinoid at night and benzoyl peroxide in the morning).</li><li>Both these drugs can irritate the skin; consider using lower strengths or switching if this is a problem.</li><li>A combined proprietary product is available.</li></ul></li><li>A topical retinoid combined with a topical antibiotic is another option.<ul><li>If two products are used separately, they should be applied 12 hours apart (for example topical retinoid at night and topical antibiotic in the morning).</li><li>Combined proprietary products are available.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">BNF 74, 2017</a>]</p><!-- end field 517ee9c9-4ea0-4150-9623-113e494a0890 --><!-- end item e98def1f-243e-4d3b-9d6a-a46892bf760e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}